View Older Stories View More Recent Stories

Nov 6, 2019 07:40AM Biogen (BIIB) announced new proposed transaction with Samsung Bioepis
Nov 6, 2019 07:30AM Biogen to Expand Biosimilars Portfolio and Gain Access to Additional Markets Through New Transaction with Samsung Bioepis
Nov 6, 2019 07:30AM Biogen to Expand Biosimilars Portfolio and Gain Access to Additional Markets Through New Transaction with Samsung Bioepis
Nov 4, 2019 04:30PM Biogen to Host Investor Webcasts from Clinical Trials on Alzheimer’s Disease (CTAD) Congress on December 5, 2019
Nov 4, 2019 04:30PM Biogen to Host Investor Webcasts from Clinical Trials on Alzheimer’s Disease (CTAD) Congress on December 5, 2019
Oct 30, 2019 07:40AM Biogen (BIIB), Alkermes (ALKS) Report FDA Approval of VUMERITY (diroximel fumarate) for Multiple Sclerosis
Oct 30, 2019 07:30AM Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis
Oct 30, 2019 07:30AM Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis
Oct 30, 2019 07:30AM Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis
Oct 22, 2019 06:33AM Biogen (BIIB) Says it Plans Regulatory Filing for Aducanumab in Alzheimer's Disease After Consulting with FDA
Oct 22, 2019 06:30AM Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies
Oct 22, 2019 06:30AM Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies
Oct 21, 2019 07:30AM Biogen and Samsung Bioepis to Present Data for Infliximab and Adalimumab Biosimilars at United European Gastroenterology Week
Oct 21, 2019 07:30AM Biogen and Samsung Bioepis to Present Data for Infliximab and Adalimumab Biosimilars at United European Gastroenterology Week
Oct 2, 2019 07:36AM Biogen (BIIB) Announces Landmark NURTURE Study of Infants with SMA Treated Pre-Symptomatically with SPINRAZA Published in Neuromuscular Disorders
Oct 2, 2019 07:30AM Landmark NURTURE Study of Infants with Spinal Muscular Atrophy (SMA) Treated Pre-Symptomatically with SPINRAZA® (nusinersen) Published in Neuromuscular Disorders
Oct 2, 2019 07:30AM Landmark NURTURE Study of Infants with Spinal Muscular Atrophy (SMA) Treated Pre-Symptomatically with SPINRAZA® (nusinersen) Published in Neuromuscular Disorders
Oct 1, 2019 08:05AM Biogen (BIIB) announces Michael D. Ehlers, M.D., Ph.D., has decided to step down as EVP, Research and Development
Oct 1, 2019 08:00AM Biogen Announces Leadership Update
Oct 1, 2019 08:00AM Biogen Announces Leadership Update
Sep 23, 2019 05:54AM Biogen (BIIB) Reports Interferon Beta Treatments, Including PLEGRIDY (peginterferon beta-1a) & AVONEX (interferon beta-1a), Positive Receive Positive CHMP Opinion
Sep 23, 2019 03:00AM Interferon Beta Treatments, Including PLEGRIDY® (peginterferon beta-1a) and AVONEX® (interferon beta-1a), Receive Positive CHMP Opinion for Use During Pregnancy and Breastfeeding
Sep 23, 2019 03:00AM Interferon Beta Treatments, Including PLEGRIDY® (peginterferon beta-1a) and AVONEX® (interferon beta-1a), Receive Positive CHMP Opinion for Use During Pregnancy and Breastfeeding
Sep 18, 2019 07:34AM Biogen (BIIB) Reports Initiation of New Global Clinical Trial, DEVOTE, Evaluating Higher Dose of SPINRAZA (nusinersen) & Additional Data
Sep 18, 2019 07:30AM Biogen Advances Spinal Muscular Atrophy (SMA) Clinical Research with New Study Evaluating a Higher Dose of SPINRAZA® (nusinersen) and Additional Data in a Broad Range of Patients
Sep 18, 2019 07:30AM Biogen Advances Spinal Muscular Atrophy (SMA) Clinical Research with New Study Evaluating a Higher Dose of SPINRAZA® (nusinersen) and Additional Data in a Broad Range of Patients
Sep 17, 2019 07:30AM Biogen Ranked #1 Biotechnology Company on Dow Jones Sustainability World Index
Sep 17, 2019 07:30AM Biogen Ranked #1 Biotechnology Company on Dow Jones Sustainability World Index
Sep 13, 2019 08:01AM Eisai And Biogen (BIIB) to Discontinue Phase III Clinical Studies Of BACE Inhibitor Elenbecestat In Early Alzheimer's Disease
Sep 13, 2019 08:00AM Eisai And Biogen To Discontinue Phase III Clinical Studies Of BACE Inhibitor Elenbecestat In Early Alzheimer's Disease
Sep 12, 2019 05:00AM New Research Demonstrate Biogen’s Continued Commitment to Improve Care of Patients with Multiple Sclerosis Across Treatment Spectrum
Sep 12, 2019 05:00AM New Research Demonstrate Biogen’s Continued Commitment to Improve Care of Patients with Multiple Sclerosis Across Treatment Spectrum
Sep 11, 2019 06:23AM Biogen (BIIB) Says New Data Presented at ECTRIMS Reinforce Long-term Benefits of TECFIDERA Over 10 Years
Sep 11, 2019 05:00AM New Data Presented at ECTRIMS Reinforce Long-term Benefits of TECFIDERA® (dimethyl fumarate) Over 10 Years
Sep 11, 2019 05:00AM New Data Presented at ECTRIMS Reinforce Long-term Benefits of TECFIDERA® (dimethyl fumarate) Over 10 Years
Aug 20, 2019 07:30AM Biogen and Invitae Announce Availability of Rapid Results in Genetic Testing Program for Spinal Muscular Atrophy (SMA) to Improve Speed of Diagnosis for Patients
Aug 20, 2019 07:30AM Biogen and Invitae Announce Availability of Rapid Results in Genetic Testing Program for Spinal Muscular Atrophy (SMA) to Improve Speed of Diagnosis for Patients
Jul 30, 2019 07:30AM Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis
Jul 30, 2019 07:30AM Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis
Jul 30, 2019 07:30AM Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis
Jul 1, 2019 07:32AM Biogen (BIIB) Announces New Data Further Establishing SPINRAZA as Foundation of Care in SMA for Broad Range of Patients
Jul 1, 2019 07:30AM Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients
Jul 1, 2019 07:30AM Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients
Jul 1, 2019 07:30AM Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients
Jun 11, 2019 07:05PM Biogen to Present New Safety and Efficacy Data on Biosimilars and Estimates 1.8 Billion Euros in Savings for the European Healthcare System in 2019
Jun 11, 2019 07:05PM Biogen to Present New Safety and Efficacy Data on Biosimilars and Estimates 1.8 Billion Euros in Savings for the European Healthcare System in 2019
Jun 7, 2019 08:07AM Biogen (BIIB) Completes Acquisition of Nightstar Therapeutics (NITE)
Jun 7, 2019 05:41AM Biogen Completes Acquisition of Nightstar Therapeutics for Approximately $800 Million
Jun 7, 2019 05:41AM Biogen Completes Acquisition of Nightstar Therapeutics for Approximately $800 Million
May 30, 2019 07:36AM Biogen (BIIB) Announces New Phase 3 Interim Results Support Safety & Efficacy of Diroximel Fumarate in Multiple Sclerosis
View More Recent Stories View Older Stories